Edition:
United States

Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

2.23CAD
24 Mar 2017
Change (% chg)

$0.06 (+2.76%)
Prev Close
$2.17
Open
$2.25
Day's High
$2.29
Day's Low
$2.19
Volume
1,073,755
Avg. Vol
2,344,179
52-wk High
$3.49
52-wk Low
$1.47

PLI.TO

Chart for PLI.TO

About

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various... (more)

Overall

Beta: 2.75
Market Cap(Mil.): $1,491.18
Shares Outstanding(Mil.): 668.69
Dividend: --
Yield (%): --

Financials

  PLI.TO Industry Sector
P/E (TTM): -- 29.17 29.94
EPS (TTM): -0.13 -- --
ROI: -44.37 13.48 13.01
ROE: -60.78 14.39 14.16

BRIEF-ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis Phase 2 Clinical Trial

* ProMetic's PBI-4050 demonstrates early evidence of efficacy in its idiopathic pulmonary fibrosis ("IPF") phase 2 clinical trial Source text for Eikon: Further company coverage:

Nov 17 2016

BRIEF-Prometic's PBI-4050 demonstrates early evidence of efficacy in its IPF Phase 2 clinical trial

* Early evidence of efficacy of PBI-4050 alone and also in combination with one of commercially available IPF drugs

Nov 17 2016

BRIEF-Prometic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial

* Says phase 2 clinical trial on pbi-4050 expected to commence in Q4 2016

Nov 16 2016

BRIEF-Prometic life sciences PBI-4050 shown to reduce pulmonary hypertension

* Prometic Life Sciences - PBI-4050 shown to reduce pulmonary hypertension and lung remodeling and to improve right ventricular function in heart failure

Nov 14 2016

BRIEF-Prometic announces closing of Telesta Therapeutics acquisition

* Prometic announces closing of Telesta Therapeutics Inc Acquisition Source text for Eikon: Further company coverage:

Oct 31 2016

BRIEF-Telesta Therapeutics announces final court approval of plan of arrangement with Prometic Life Sciences

* Announces final court approval of plan of arrangement with Prometic Life Sciences Inc

Oct 28 2016

BRIEF-Telesta Therapeutics shareholders approve plan of arrangement with Prometic Life Sciences

* Telesta Therapeutics Inc. shareholders approve plan of arrangement with Prometic Life Sciences Inc.

Oct 25 2016

BRIEF-Prometic's PBI-4050 meets primary end point

* Prometic's PBI-4050 meets primary and secondary end points in metabolic syndrome and type 2 diabetes phase 2 clinical trial

Oct 20 2016

BRIEF-Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome

* Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome

Oct 12 2016

BRIEF-Telesta says ISS, Glass Lewis recommend shareholders vote for plan of arrangement between co, Prometic Life Sciences

* Leading independent advisory firms ISS and Glass Lewis recommend shareholders vote for the plan of arrangement Between Telesta Therapeutics Inc and Prometic Life Sciences Inc Source text for Eikon: Further company coverage:

Oct 11 2016

More From Around the Web

Earnings vs. Estimates